Lachman Prem A 4

What Happened

• Prem A. Lachman, a director of OPKO Health, received an award/derivative grant of 30,000 shares on 2026-06-18. The Form 4 lists the acquisition price as $0.00 (no cash paid). The filing classifies the transaction as an award/other acquisition (code A) of a derivative security.
• This was a compensation/award transaction rather than an open-market purchase or sale, so it reflects company-issued shares (likely restricted stock or RSUs), not a personal cash investment.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22 (filed within the SEC’s two-business-day window for Form 4s).
• Shares acquired: 30,000; reported purchase price: $0.00 (no cash exchanged).
• Security type: Derivative (award/grant). Form 4 does not specify vesting or restriction details in the provided summary.
• Shares owned after transaction: not disclosed in the provided data.
• No footnotes (e.g., 10b5-1 plan, tax withholding) were reported in the information provided.

Context

• Awards to directors are commonly part of board compensation and do not necessarily signal a personal bullish or bearish view by the insider. Because this was an award (not a market buy), it’s best viewed as compensation-related rather than an investment decision.
• For retail investors tracking insider activity, purchases on the open market tend to be more informative about an insider’s personal conviction than awards or grants.